Sansure Biotech Inc Capital Reinvestment Ratio
Sansure Biotech Inc capital reinvestment ratio. Sansure Biotech Inc (688289) has a Capital Reinvestment Ratio of 1.06x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥59.72 Million) in capital expenditures (CN¥63.08 Million). See Sansure Biotech Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Sansure Biotech Inc (2018–2025)
Capital reinvestment ratio of Sansure Biotech Inc from 2018 to 2025. This chart tracks Sansure Biotech Inc's Capital Reinvestment Ratio across 8 annual periods. See financial agility of Sansure Biotech Inc to measure the company's free cash flow as a share of total liabilities.
Sansure Biotech Inc Capital Reinvestment Ratio by Year (2018–2025)
Sansure Biotech Inc capital reinvestment ratio by year from 2018 to 2025. For the full cash flow conversion analysis, see Sansure Biotech Inc cash conversion from operations.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 2.01x | CN¥183.96 Million | CN¥369.77 Million | ▲ +31.0% |
| 2024 | 1.53x | CN¥274.45 Million | CN¥421.10 Million | ▼ -55.8% |
| 2023 | 3.47x | CN¥112.82 Million | CN¥391.35 Million | ▲ +1488.4% |
| 2022 | 0.22x | CN¥2.56 Billion | CN¥558.83 Million | ▲ +9.9% |
| 2021 | 0.20x | CN¥1.88 Billion | CN¥372.86 Million | ▲ +383.0% |
| 2020 | 0.04x | CN¥2.64 Billion | CN¥108.67 Million | ▼ -97.3% |
| 2019 | 1.52x | CN¥22.41 Million | CN¥34.14 Million | ▼ -53.4% |
| 2018 | 3.27x | CN¥10.07 Million | CN¥32.90 Million | — |